Treatment-Naive Genotype 4 With Compensated Cirrhosis

Recommended and alternative regimens listed by pangenotypic, evidence level and alphabetically for: Treatment-Naive Genotype 4 Patients With Compensated Cirrhosis^a
RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)^b	8 weeks^c	I, B
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)	12 weeks	IIa, B
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	IIa, B
^a For decompensated cirrhosis, please refer to the appropriate section. ^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. ^c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended.

Last update:

October 24, 2022

Treatment-Naive Genotype 4 Patients With Compensated Cirrhosisa